NAV

Dipropyl-4-hydroxytryptamine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Dipropyl-4-hydroxytryptamine
DrugBank Accession Number
DB13990
Background

Dipropyl-4-hydroxytryptamine is the 4-hydroxyl analog of dipropyltryptamine (DPT). Dipropyl-4-hydroxytryptamine was first synthesized by Alexander Shulgin. This agent and its properties haven't been fully elucidated.

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 260.381
Monoisotopic: 260.188863401
Chemical Formula
C16H24N2O
Synonyms
  • 3-[2-(Dipropylamino)ethyl]-1H-indol-4-ol
  • 4-HO-DPT
  • 4-Hydroxy-N,N-dipropyltryptamine
  • 4-Hydroxydipropyltryptamine
  • Deprocin
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
KS597YAU98
CAS number
63065-88-3
InChI Key
MZLRMPTVOVJXLW-UHFFFAOYSA-N
InChI
InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-12-17-14-6-5-7-15(19)16(13)14/h5-7,12,17,19H,3-4,8-11H2,1-2H3
IUPAC Name
3-[2-(dipropylamino)ethyl]-1H-indol-4-ol
SMILES
CCCN(CCC)CCC1=CNC2=C1C(O)=CC=C2

References

General References
Not Available
ChemSpider
10579817
Wikipedia
4-HO-DPT

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.367 mg/mLALOGPS
logP4.04ALOGPS
logP2.51Chemaxon
logS-2.8ALOGPS
pKa (Strongest Acidic)9.1Chemaxon
pKa (Strongest Basic)10.66Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area39.26 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity80.97 m3·mol-1Chemaxon
Polarizability31.29 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-1790000000-21db15b2ab90402b9f65
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0090000000-be2baf338ce1ae3df474
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-1920000000-f9f07ee097c6a50b545f
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-052f-0940000000-2ade18b6e505771a0af6
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-01x3-6900000000-6d5322db7d13b8338246
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-000w-0900000000-c4cbccc88fa46524f513
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-170.9038505
predicted
DarkChem Lite v0.1.0
[M+H]+171.1685505
predicted
DarkChem Lite v0.1.0
[M+Na]+171.2196505
predicted
DarkChem Lite v0.1.0

Drug created at February 19, 2018 23:57 / Updated at June 12, 2020 16:53